C12N 2750/14351
Methods of production or purification of viral material
C12N2750/14351 (Methods of production or purification of viral material) appears on 29 US grants and 42 published applications in this corpus.
Search patents in C12N- Granted patents
- 29
- Published applications
- 42
- Assignees
- 25
- Inventors
- 71
- Latest grant
- 2 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 2 |
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 1 | 1 |
| 2012 | 1 | 2 |
| 2013 | 0 | 3 |
| 2014 | 0 | 5 |
| 2015 | 3 | 2 |
| 2016 | 2 | 2 |
| 2017 | 5 | 2 |
| 2018 | 1 | 4 |
| 2019 | 3 | 5 |
| 2020 | 3 | 2 |
| 2021 | 2 | 1 |
| 2022 | 0 | 3 |
| 2023 | 1 | 2 |
| 2024 | 1 | 1 |
| 2025 | 3 | 2 |
By publication year. Applications have been published since 2001.
Subgroups
Granted patents
Recent patents
- Optimized parvovirus H-1 production2 Sep 2025US 12,404,498 B2Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Canine parvovirus (CPV) nanobody CPV-VHH-H1 and use thereof29 Jul 2025US 12,371,476 B2Institute of Animal Sciences of Caas
- Establishment and suspension acclimation of CRFK adherent cell line, and its application29 Apr 2025US 12,286,647 B1Taizhou Bioally Technology Co., Ltd.
- Restrictive inverted terminal repeats for viral vectors26 Mar 2024US 11,939,597 B2The University of North Carolina at Chapel Hill
- Restrictive inverted terminal repeats for viral vectors3 Jan 2023US 11,542,478 B2The University of North Carolina at Chapel Hill
- Establishment and suspension acclimation of crfk adherent cell line, and its application24 Apr 2025US 2025/0129341 A1Taizhou Bioally Technology Co., Ltd.
- Method for further upscaling the large-scale production of the oncolytic h-1 protoparvovirus (h-1pv) using a carrier-based production process combined with an optimized cell culture medium6 Feb 2025US 2025/0043251 A1
- Protoparvovirus and tetraparvovirus compositions and methods for gene therapy29 Feb 2024US 2024/0066080 A1Synteny Therapeutics, Inc.
- Canine parvovirus (cpv) nanobody cpv-vhh-h1 and use thereof22 Jun 2023US 2023/0192815 A1Institute of Animal Sciences of Chinese Academy of Agricultural Sciences
- Restrictive inverted terminal repeats for viral vectors1 Jun 2023US 2023/0167418 A1The University of North Carolina at Chapel Hill
Most cited
By later US patents
- Restrictive inverted terminal repeats for viral vectors38US 9,169,494 B2The University of North Carolina at Chapel Hill · 2015
- Stable production of lentiviral vectors4US 9,441,245 B2MolMed SpA · 2016
- Methods and compositions for the production of recombinant virus vectors3US 8,263,396 B22012
- Feline cell capable of being cultured without animal-derived protein, and method for producing virus and method for producing vaccine using thereof2US 7,767,451 B2Kyoritsu Seiyaku Corporation · 2010
- Formulation of sugar solutions for continuous ultracentrifugation for virus purification2US 8,969,533 B2Baxter Healthcare S. A. · 2015